Anti-EGFR antibody-drug conjugate
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Anti-EGFR antibody-drug conjugate, covering 2024-07-19 to 2024-07-19. Get the full timeline:
Most recent: Clinical Trial Update: A Phase II Study of Anti-EGFR Antibody-drug Conjugate (ADC) Combine With CDK4/6 Inhibitors Posterior Line in the Treatment of Recurrent/Metastatic CDKN2A Gene Variant Head and Neck Squamous Cell Carcinoma [Phase 2]